-
GlaxoSmithKline Poaches New CSO From Google's Calico
biospace
November 10, 2017
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to shape her executive team. After poaching Luke Miels from AstraZeneca,
-
Singapore's Restalyst develops new method to improve liver cancer diagnosis
prnasia
November 09, 2017
Singapore biomedical firm Restalyst has developed a new algorithm to detect liver cancer more accurately, improving the sensitivity to 90%.
-
United States Food and Drug Administration (USFDA) - BioResearch Monitoring Program (BIMO) Conducted
prnasia
November 09, 2017
Veeda CR is glad to share the successful completion of 2 USFDA Inspections at two of its locations at Ahmedabad in Sep-2017.
-
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
fiercepharma
November 09, 2017
Bayer is working to position Stivarga as part of a treatment regimen for those who have failed on its first-line liver cancer fighter, Nexavar. But that’s not going to work in England. At least, not yet.
-
Pfizer renews 'Know Pneumonia' campaign with myth-busting creative
fiercepharma
November 09, 2017
Pfizer has relaunched its “Know Pneumonia” disease awareness campaign with a myths-and-facts approach.
-
Zebra Medical to bring AI-based image analysis to Google Cloud
fiercebiotech
November 09, 2017
Zebra Medical Vision, which last month offered its image analysis algorithms for a flat rate per scan, is teaming up with Google to offer its algorithms on the Google Cloud.
-
Roche, Calico vet Hal Barron takes GSK R&D hot seat, as Vallance out
fiercebiotech
November 09, 2017
Former Roche and Calico vet Hal Barron has become the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley.
-
Long-Term Use of Taltz Shows Efficacy Improvements in Psoriatic Arthritis
americanpharmaceuticacreview
November 09, 2017
"In addition to the efficacy of Taltz for people with skin symptoms, we are pleased to share new data suggesting that Taltz, if approved, may provide an option for those with joint symptoms of PsA."
-
BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans
americanpharmaceuticacreview
November 09, 2017
Consistent with oral minocycline products, BPX-01 is intended for the targeted treatment of non-nodular inflammatory acne vulgaris.
-
OncoSec Announces Positive Data from Trial of ImmunoPulse IL-12, Pembrolizumab
americanpharmaceuticacreview
November 09, 2017
The updated clinical and correlative immune-focused biomarker data demonstrated a 57% progression free survival (PFS) rate at 15 months with 100% (11/11) duration of response and median PFS not yet reached.